Page 25 of 25
Evaluation of company clinical trial reports could provide information for meta-analysis at the commercial introduction of a new technology.
Citation: BMC Urology 2002 2:6
In spinal cord injury (SCI) patients, no correlation was found between the number of bladder infections per year, the period since injury, the neurologic level of the spinal cord lesion and the histopathology ...
Citation: BMC Urology 2002 2:5
Sildenafil (Viagra®) is one of the drugs used in the first line therapy of male erectile dysfunction (MED). We have recorded outcomes, adverse events and acceptability of Sildenafil (Viagra) therapy in an unselec...
Citation: BMC Urology 2002 2:4
Testicular microlithiasis is a rare, usually asymptomatic, non-progressive disease of the testes associated with various genetic anomalies, infertility and testicular tumors. According to our literature search...
Citation: BMC Urology 2002 2:3
Finasteride, a 5 alpha reductase inhibitor, is an established treatment for benign prostatic hyperplasia. The recommended dosage is 5 mg a day, however case reports have show effectiveness with lower doses. Th...
Citation: BMC Urology 2002 2:2
Primary renal carcinoid is extremely rare and there are few reports on the natural history of the disease.
Citation: BMC Urology 2002 2:1
A delay in diagnosis or a misdiagnosis may occur in patients with spinal cord injury (SCI) or spinal bifida as typical symptoms of a clinical condition may be absent because of their neurological impairment.
Citation: BMC Urology 2001 1:3
To present a protocol of a prospective, cohort study in which four groups of spinal cord injury (SCI) patients will participate. (Patients with indwelling urethral catheter; patients who perform intermittent c...
Citation: BMC Urology 2001 1:2
In this study a new instrument and technique is described for the endoscopic treatment of complete posterior urethral strictures, which may result in serious complications and sometimes require troublesome tre...
Citation: BMC Urology 2001 1:1
BMC Urology works with with Cochrane Urology in providing our authors with expert advice on systematic reviews and meta-analyses
As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time. Thank you.
Citation Impact
1.592 - 2-year Impact Factor
1.818 - 5-year Impact Factor
0.873 - Source Normalized Impact per Paper (SNIP)
0.693 - SCImago Journal Rank (SJR)
Usage
411.226 downloads
Social Media Impact
322 Altmetric mentions
